BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
calcium channel activity
,
Inflammatory disorder
,
Endothelial cell
,
Autoimmunity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
kinesin
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Connective tissue fibrosarcoma HT-1080 cells with KIF20A gene knockdown
Prostate cancer C4-2B cells enzalutamide resistant with KIF15 siRNA knockdown
Taxane resistance in breast cancer after paclitaxel treatment
Manipulation of RNA helicase A and KIF1Bbeta in a neuroblastoma cell line
Naive and memory CD4+ T cells from healthy donors stimulated with anti-CD3 anti-CD28 antibodies
Explore Curated Studies Results
Literature
Most Relevant Literature
Determinant factors for residence time of kinesin motors at microtubule ends.
Modeling study of kinesin-13 MCAK microtubule depolymerase.
Molecular mechanism of interaction between kinesin motors affecting their residence times on microtu…
The two-step cargo recognition mechanism of heterotrimeric kinesin.
A synthetic ancestral kinesin-13 depolymerizes microtubules faster than any natural depolymerizing k…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Adv…
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ